The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research Journal Article
| Authors: | Cheever, M. A.; Allison, J. P.; Ferris, A. S.; Finn, O. J.; Hastings, B. M.; Hecht, T. T.; Mellman, I.; Prindiville, S. A.; Viner, J. L.; Weiner, L. M.; Matrisian, L. M. |
| Article Title: | The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research |
| Abstract: | The purpose of the National Cancer Institute pilot project to prioritize cancer antigens was to develop a well-vetted, priority-ranked list of cancer vaccine target antigens based on predefined and preweighted objective criteria. An additional aim was for the National Cancer Institute to test a new approach for prioritizing translational research opportunities based on an analytic hierarchy process for dealing with complex decisions. Antigen prioritization involved developing a list of "ideal" cancer antigen criteria/characteristics, assigning relative weights to those criteria using pairwise comparisons, selecting 75 representative antigens for comparison and ranking, assembling information on the predefined criteria for the selected antigens, and ranking the antigens based on the predefined, preweighted criteria. Using the pairwise approach, the result of criteria weighting, in descending order, was as follows: (a) therapeutic function, (b) immunogenicity, (c) role of the antigen in oncogenicity, (d) specificity, (e) expression level and percent of antigen-positive cells, (f) stem cell expression, (g) number of patients with antigen-positive cancers, (h) number of antigenic epitopes, and (i) cellular location of antigen expression. None of the 75 antigens had all of the characteristics of the ideal cancer antigen. However, 46 were immunogenic in clinical trials and 20 of them had suggestive clinical efficacy in the "therapeutic function" category. These findings reflect the current status of the cancer vaccine field, highlight the possibility that additional organized efforts and funding would accelerate the development of therapeutically effective cancer vaccines, and accentuate the need for prioritization. © 2009 American Association for Cancer Research. |
| Keywords: | clinical trials as topic; united states; neoplasm; neoplasms; antigen expression; t lymphocyte; prostate specific antigen; glycoprotein gp 100; cancer immunotherapy; carcinoembryonic antigen; epidermal growth factor receptor; protein p53; survivin; tumor antigen; stem cell; oncogene; antigens, neoplasm; cancer vaccine; recombinant gamma interferon; cancer vaccines; antigen specificity; ganglioside gd2; pilot projects; melanoma antigen 1; melanoma antigen 3; ny eso 1 antigen; immunogenicity; epitope; polysialic acid; carcinogenicity; telomerase reverse transcriptase; clinical research; cellular distribution; androgen receptor; melan a; ras protein; bcr abl protein; cyclin b1; cytochrome p450 1b1; ephrin receptor a2; epithelial cell adhesion molecule; ganglioside gm1; ganglioside gm3; monophenol monooxygenase; mucin 1; myeloblastin; transcription factor pax3; national cancer institute (u.s.); program development |
| Journal Title: | Clinical Cancer Research |
| Volume: | 15 |
| Issue: | 17 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2009-09-01 |
| Start Page: | 5323 |
| End Page: | 5337 |
| Language: | English |
| DOI: | 10.1158/1078-0432.ccr-09-0737 |
| PUBMED: | 19723653 |
| PROVIDER: | scopus |
| PMCID: | PMC5779623 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 38" - "Export Date: 30 November 2010" - "CODEN: CCREF" - "Source: Scopus" |
